Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Costco has crossed $950 for the first time since the September earnings day, but two quieter stories are worth watching alongside the headline price move: a 13-quarter unbroken decline in buyback capacity, and a valuation multiple that has expanded further even as analysts trim their targets.
The stock closed Tuesday at $954.63, up 2% on the week and roughly 5.5% over the past month. That momentum has kept COST well ahead of close peers: WMT gained a similar 4.7% on the week and BJ rose 4.1%, so the move is less a Costco-specific re-rating and more a broad lift in warehouse and discount retail. lagged, falling 2.9% on Tuesday alone, a reminder that not all grocery-adjacent names are benefiting equally.
Options positioning has eased slightly from the bullish extreme reached last week. The put/call ratio ticked up from around 0.88 to 0.90, still nearly a full standard deviation below its 20-day average of 0.95, and well off September's elevated range when the PCR was running above 1.09. The borrow market remains irrelevant to the thesis: short interest is 1.6% of the free float, availability is essentially unlimited, and cost to borrow at 0.48% is the same background noise it has been all year. There is no short-side pressure, and none is building.
The analyst picture is one of calibrated caution at a premium price. After the September 24 earnings beat, most of the Street maintained ratings but pulled back price targets. JP Morgan's Christopher Horvers cut from $1,100 to $1,015 while keeping Overweight. Raymond James trimmed from $1,100 to $1,050, also Outperform. Deutsche Bank lowered its target to $1,079, still Buy. RBC reiterated Sector Perform at $1,000 as recently as October 9. The consensus mean is $1,060, implying roughly 11% upside from current levels, but the direction of target revisions has been uniformly downward. The trailing P/E has expanded to 38.9x, up about a point over the past month, and EV/EBITDA runs near 24x. Bears point to that premium explicitly: at roughly 27x forward EBITDA versus a decade-long average closer to 20x, the stock needs membership growth and same-store momentum to keep delivering to justify the multiple. Bulls counter with 92.3% U.S. renewal rates, e-commerce that has grown to about 10% of sales from 4% in 2019, and a plan to open roughly 30 warehouses per year.
The most distinctive data point this week sits in Costco's own corporate filings. ORTEX Alt Data, drawing on SEC EDGAR XBRL disclosures, flags that the remaining buyback authorisation has fallen for 13 consecutive quarters, reaching $1.36 billion as of the April 2026 period, down 39% on the same quarter a year earlier. That is a streak worth noting in context. Costco has historically used buybacks sparingly relative to its cash generation, so the declining authorisation is less a distress signal and more a measure of management's capital-allocation priorities, with elevated capex for new warehouses absorbing the available firepower. It does, however, limit one potential source of per-share EPS support heading into the December 10 print.
Insider activity is routine rather than directional. The most recent open-market transactions were two discretionary sales in late September: EVP Claudine Adamo sold 2,200 shares at $915.93, and SVP Caton Frates sold roughly 800 shares at the same price, together totalling about $2.75 million. The September 10 activity was compensation mechanics, stock awards accompanied by tax-withholding sales, not conviction trades. Net insider activity over 90 days is a modest negative at roughly 3,000 shares sold, which tells you very little about direction.
With earnings on December 10, the setup to watch is whether monthly sales data between now and then, and any commentary on membership trends, either confirms or complicates the bullish case at a P/E north of 38x.
See the live data behind this article on ORTEX.
Open COST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.